Intranasal analgesia developer Trigemina Inc. has announced the appointment of Shashidhar “Shashi” Kori as Chief Medical Officer. Trigemina’s TI-114 intranasal oxytocin, is in Phase 2 development for the treatment of migraine headaches; the company is also developing an intranasal polypeptide for somatic pain.
Kori was most recently Chief Medical officer at Autonomic Technologies. He has also served as VP of Clinical Development and Medical Affairs at MAP Pharmaceuticals and Senior Director of Clinical Development at GSK, among other positions.
Trigemina President and CEO Charles Yeomans commented, “We are thrilled to add Dr. Kori to our clinical team given his vast experience managing clinical development at leading biotech companies and more specifically in the headache space. Shashi’s experience in clinical trial design and product development will be key as we continue to advance our lead product, TI-114, toward a pivotal trial for migraine headaches.”
Kori said,”The human clinical data that Trigemina has produced to date with its intranasal oxytocin product for migraine headaches have been very promising, and I am thrilled to be a part of the team that will see this product through late-stage clinical trials. The strong interest in Trigemina’s migraine drug candidate that is being shown by key opinion leaders in the headache and pain space is inspiring, and I look forward to teaming up with internal and external thought leaders to advance these products toward commercialization.”
Read the Trigemina press release.
